Published online before print August 29, 2006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

* Unitat de Bioquímica, Departament de Ciències Fisiològiques II, IDIBELL-Universitat de Barcelona, Campus de Bellvitge, LHospitalet de Llobregat, Barcelona, Spain; and
Servei dHematologia, IDIBELL-Hospital Universitari de Bellvitge, Campus de Bellvitge, LHospitalet de Llobregat, Barcelona, Spain
2 Correspondence: Departament de Ciències Fisiològiques II, IDIBELL-Universitat de Barcelona, Campus de Bellvitge, Pavelló de Govern, 4ª planta, LHospitalet de Llobregat, Barcelona E-08907, Spain. E-mail: jgil{at}ub.edu
Apoptosis of B cell chronic lymphocytic leukemia (B-CLL) cells is regulated by the PI-3K-Akt pathway. In the present work, we have analyzed the mechanisms of Akt phosphorylation in B-CLL cells. Freshly isolated cells present basal Akt phosphorylation, which is PI-3K-dependent, as incubation with the PI-3K inhibitor LY294002 decreased Ser-473 and Thr-308 phosphorylation in most samples analyzed (seven out of 10). In three out of 10 cases, inhibition of protein kinase C (PKC) inhibited basal Akt phosphorylation. Stromal cell-derived factor-1
, IL-4, and B cell receptor activation induced PI-3K-dependent Akt phosphorylation. PMA induced the phosphorylation of Akt at Ser-473 and Thr-308 and the phosphorylation of Akt substrates, independently of PI-3K in B-CLL cells. In contrast, PKC-mediated phosphorylation of Akt was PI-3K-dependent in normal B cells. Finally, a specific inhibitor of PKCβ blocked the phosphorylation and activation of Akt by PMA in B-CLL cells. Taken together, these results suggest a model in which Akt could be activated by two different pathways (PI-3K and PKCβ) in B-CLL cells.
Key Words: apoptosis signal transduction
This article has been cited by other articles:
![]() |
M. de Frias, D. Iglesias-Serret, A. M. Cosialls, L. Coll-Mulet, A. F. Santidrian, D. M. Gonzalez-Girones, E. de la Banda, G. Pons, and J. Gil Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells Haematologica, December 1, 2009; 94(12): 1698 - 1707. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Holler, J. D. Pinon, U. Denk, C. Heyder, S. Hofbauer, R. Greil, and A. Egle PKC{beta} is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC{beta} as a therapeutic target in chronic lymphocytic leukemia Blood, March 19, 2009; 113(12): 2791 - 2794. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hewamana, T. T. Lin, C. Rowntree, K. Karunanithi, G. Pratt, R. Hills, C. Fegan, P. Brennan, and C. Pepper Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia J. Clin. Oncol., February 10, 2009; 27(5): 763 - 769. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Grozinsky-Glasberg, I. Shimon, M. Korbonits, and A. B Grossman Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms Endocr. Relat. Cancer, September 1, 2008; 15(3): 701 - 720. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Y. Follo, S. Mongiorgi, C. Bosi, A. Cappellini, C. Finelli, F. Chiarini, V. Papa, M. Libra, G. Martinelli, L. Cocco, et al. The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation Cancer Res., May 1, 2007; 67(9): 4287 - 4294. [Abstract] [Full Text] [PDF] |
||||